George Chen, WG’99

In 2020, George Chen left AZ Global R&D, where he was an SVP, to start his own biotech focusing on oncology. In late 2020, George raised $200 million to launch his own biotech, D3 Bio. In the last 2.5 years, D3 Bio has become a global, clinical-stage biotech with three internally discovered assets (2 small molecules and 1 bi-specific antibody) entering clinical development globally. This is a fantastic achievement for biotech formed only 2.5 years ago. Will keep you all posted on D3 Bio’s future progress.


Contact George at: [email protected]

Back to the Alumni News list.